<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668314</url>
  </required_header>
  <id_info>
    <org_study_id>RDN-929-101</org_study_id>
    <nct_id>NCT03668314</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Doses of Orally Administered RDN-929 in Healthy Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QPS Netherlands B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A three (3) part study to evaluate the safety, tolerability and PK of RDN-929
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 (Randomized, Double Blind):

      Up to 6 single ascending doses of RDN-929 are planned to be tested in 6 cohorts of 8 healthy
      males (Cohort 1:1 to 1:6). Within each cohort subjects will be randomly assigned to receive
      either a single dose of RDN-929 (6 subjects) or matched placebo (2 subjects).

      Part 2 (Open):

      Part 2 will consist of 2 crossover treatment periods in one cohort of 12 healthy elderly
      subjects (at least 3 of each gender), aged 55-80 years. The treatments will be separated by a
      washout period of at least 7 days. The dose selected for this part of the study will be based
      on the results of Part 1.

      In Period 1, subjects will be randomized to receive a single dose of RDN-929 in either fasted
      or fed status. In Period 2, subjects will receive a single dose of RDN-929 under the
      alternate status.

      Part 3 (Randomized, Double Blind):

      Multiple ascending doses (MAD) of RDN-929 are planned to be tested in up to 4 cohorts of 8
      healthy elderly subjects (at least 3 of each gender per dose level cohort), aged 55-80 years.
      The doses will be selected by the safety review committee (SRC) based on all available
      safety, tolerability and PK data and after approval by the ethics committee.

      Within each cohort subjects will be randomly assigned to receive either, RDN-929 once daily
      (6 subjects) or matched placebo (2 subjects) once daily for 12 days. Escalation to the next
      higher dose level will be based upon a review of the safety and tolerability data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">April 15, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parts 1 and 3 are parallel designs with escalating doses within each part. Part 2 is a FE cross-over study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Screening to end of study, up to 7 weeks</time_frame>
    <description>Listing and summary of AE incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Physical exam findings</measure>
    <time_frame>Screening to end of study, up to 7 weeks</time_frame>
    <description>Listing of clinically significant changes in PE findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Clinical safety lab changes</measure>
    <time_frame>Screening to end of study, up to 7 weeks</time_frame>
    <description>Listing and change from baseline to end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Systolic blood pressure changes</measure>
    <time_frame>Screening to end of study, up to 7 weeks</time_frame>
    <description>Listing and change from baseline to end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Heart rate changes</measure>
    <time_frame>Screening to end of study, up to 7 weeks</time_frame>
    <description>Listing and change from baseline to end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with 12 Lead ECG changes</measure>
    <time_frame>Screening to end of study, up to 7 weeks</time_frame>
    <description>Change in 12-lead ECG parameters from baseline to end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with 3 Lead ECG findings</measure>
    <time_frame>Predose to 8 hours post dose on Day 1 (Parts 1 and 2) and Days 1 and 12 (Part 3)</time_frame>
    <description>Listing of findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with C-SSRS changes</measure>
    <time_frame>Baseline to end of study (Part 3 only), up to 7 weeks</time_frame>
    <description>Listing of results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Visual analogue scale changes</measure>
    <time_frame>Baseline to end of study for Part 1 and 3, up to 7 weeks</time_frame>
    <description>VAS for headache and nausea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration, Cmax</measure>
    <time_frame>Predose to 48 hours post first and last dose, up to 2 days (Parts 1 and 2) and 2 weeks (Part 3)</time_frame>
    <description>Of RDN-929 and primary metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed plasma concentration, Tmax</measure>
    <time_frame>Predose to 48 hours post first and last dose, up to 2 days (Parts 1 and 2) and 2 weeks (Part 3)</time_frame>
    <description>Of RDN-929 and primary metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the plasma concentration time curve, AUC</measure>
    <time_frame>Predose to 48 hours post last dose, up to 2 days (Parts 1 and 2) and 2 weeks (Part 3)</time_frame>
    <description>Of RDN-929 and primary metabolite</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1:1 - 1:6 RDN-929</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDN-929 single dose capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1:1 - 1:6 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single dose capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2:1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed/Fast RDN-929</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3:1- 3:4 RDN-929</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDN-929 multiple dose capsules once daily for 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3:1- 3:4 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo multiple dose capsules once daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDN-929</intervention_name>
    <description>Single dose from 2 mg to TBD</description>
    <arm_group_label>Cohort 1:1 - 1:6 RDN-929</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Matching placebo Single dose</description>
    <arm_group_label>Cohort 1:1 - 1:6 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDN-929 TBD dose</intervention_name>
    <description>Fed vs fast dose TBD based upon results of previous cohorts</description>
    <arm_group_label>Cohort 2:1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDN-929</intervention_name>
    <description>Multiple dose based on results of previous cohorts</description>
    <arm_group_label>Cohort 3:1- 3:4 RDN-929</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Matching placebo multiple dose</description>
    <arm_group_label>Cohort 3:1- 3:4 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by the Investigator, based on a medical evaluation including
             medical history physical examination, neurological examination, laboratory tests and
             cardiac monitoring

          -  Men, age 18-54 years inclusive at Screening (Part 1) or men and postmenopausal or
             surgically sterile women age 55-80

        Exclusion Criteria:

          -  Any history of major psychiatric disorders, including substance use disorders,
             according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
             (DSM-5) criteria.

          -  Acute suicidality or history of suicidal behavior.

          -  Alanine aminotransferase or aspartate aminotransferase levels greater than 1.5 times
             the upper limit of normal (ULN) at Screening. One retest is allowed.

          -  A corrected QT interval measurement corrected according to the Fridericia rule (QTcF)
             &gt; 450 msec during controlled rest at screening or between screening and first dose
             administration, or family history of long QT syndrome.

          -  Any clinically significant abnormalities in rhythm, conduction, or morphology of the
             resting ECG and any abnormalities in the 12-lead ECG that, in the judgement of the
             Investigator or Medical Monitor, may interfere with the interpretation of QTc interval
             changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.

          -  A clinically significant vital signs abnormality at screening or between screening and
             first dose administration. This includes, but is not limited to, the following, in the
             supine position: (a) systolic blood pressure &lt; 90 or &gt;150 mmHg, (b) diastolic blood
             pressure &lt;50 or &gt; 95 mmHg, or (c) heart rate &lt; 45 or &gt;100 beats per minute.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>QPS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS Netherlands B.V.</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

